Compare Citius Pharmaceuticals Inc (CTXR) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs KraneShares Hang Seng TECH Index ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while KraneShares Hang Seng TECH Index ETF trades at $11.81 (market cap $45.04M). The key difference: KraneShares Hang Seng TECH Index ETF is far larger — about 3.3× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 29,043). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and KraneShares Hang Seng TECH Index ETF for 44 Days on average.
| CTXR | KTEC | |
|---|---|---|
Market Cap | $13.62M | $45.04M |
Volume | 132,438 | 29,043 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $18.36 |
52-Week Low | $0.48 | $11.41 |
Typical Hold Time | 17 Days | 44 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
KTEC trades at $11.81, up 1.99% with bearish technical signals from moving averages. The company reported $120.04M revenue in 2016 with improving net margin (-0.59% vs -4.88% in 2015) and positive operating cash flow of $5.81M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC shows operational improvement but faces profitability challenges with negative net income. The stock's technical weakness and volatile earnings history suggest cautious approach. Upside depends on sustained revenue growth and margin expansion in competitive tech ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
